- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01894308
En dosvarierande studie för att undersöka Testagen® TDS-Testosteron 5 % (PARC-T-D)
En studie med flera doser, enstaka perioder, fas II-dosintervall för att undersöka Testagen® TDS-Testosteron 5 % hos vuxna manliga försökspersoner
This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
48 Patients will be enrolled following 2 independent verifying blood tests of their diagnosis of Hypogonadism. there will be 4 cohorts of 12 subjects, each receiving doses of the trail materials, titrated by means of number of sprays applied. Doses will range from 10 to 70 mgs Testosterone.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Shern L. Chew, M.D., Ph.D.
- Telefonnummer: 011-44-20 034 6227
- E-post: sl.chew@thelondonclinic.co.uk
Studera Kontakt Backup
- Namn: Chandan AS Alam, MD
- Telefonnummer: 011-44-7785-717596
- E-post: calam@tdsc.us
Studieorter
-
-
-
London, Storbritannien, NW1 4LJ
- Advanced Therapies Centre, The London Clinic
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Hypogonadal Male subjects - morning testosterone level ≤300 ng/dL (10.4 ng/L).
- 18 and 75 years of age, inclusive.
- The subject is willing and able to read, understand the Subject Information Sheet and provide written informed consent.
- The subject has a body mass index (BMI) within 18-30 kg/m2.
- The subject is in otherwise good health as determined by medical history and physical examination.
- The subject is a non-smoker.
- The subject must agree to comply with the placement of an indwelling catheter on two separate occasions and the drawing of blood samples for the pharmacokinetic assessments.
- The subject is willing and able to comply with all testing and requirements defined in the protocol.
- The subject is willing and able to return to the study site for all visits.
Exclusion Criteria:
- The subject has any relevant deviations from normal in physical examination, electrocardiogram (ECG), or clinical laboratory tests, as evaluated by the investigator, particularly an elevated PSA reading >4.0 ng/ml or ALT and AST greater than 2 times the upper limit of normal, clinically significant anemia (hematocrit <35%) or renal dysfunction (creatinine >2mg/dL), active deep vein thrombosis, thromboembolic disorders or history of these conditions.
- The subject has had a clinically significant illness within 30 days preceding entry into this study.
- The subject has a history of significant neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
- The subject has a known allergy or history of hypersensitivity to Testosterone or similar compounds.
- The subject has used any prescription medication within 14 days or over-the-counter (OTC) medication or alcohol within 48 hours of dosing or intends to use any prescription or OTC medication during the study that may interfere with the evaluation of study medication.
- The subject has donated or lost a significant volume of blood (>450 mL) within four (4) weeks of the study, and their haemoglobin concentration and haematocrit have not returned to within 5% of normal.
- The subject has a Hematocrit level > 51%
- The subject has a history of substance abuse or a current positive urine drug screen or urine alcohol test.
- Alcohol consumption greater than community norms (i.e. more than 21 standard drinks per week for males).
- Subjects who have received an investigational drug or have used an investigational device in the 30 days prior to study entry.
- Subjects with an American Urological Association System Index for Prostatism score greater than 7
- Subjects with a history of prostate or breast carcinoma.
- Subjects with prostatic mass on screening physical examination.
- Subjects with a history of significant skin disease.
- Subjects with a history of sleep apnea.
- Subject with a partner with a history of breast cancer.
- Subject with a partner of child bearing potential who is not willing to use adequate contraception for the duration of the trial.
- Subject whose partner is pregnant.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Forearm dose
Half of Ss will receive their dose of Testosterone on the inner aspects of their forearms. |
10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions. A dose of product solution is delivered by means of a metered pump spray. |
|
Aktiv komparator: Chest Dose
Half of Ss will receive their dose of Testosterone on the chest. |
10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions. A dose of product solution is delivered by means of a metered pump spray. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Dose Range Measure of serum levels of testosterone in response to varying doses
Tidsram: 1 week
|
A pharmacokinetic measure of serum levels of testosterone in response to varying doses of from 10 to 70 mgs of Testosterone. |
1 week
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Dermal Safety as measured by
Tidsram: 1 Week
|
Incidence of treatment-emergent side effects. |
1 Week
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Shern L. Chew, M.D., Ph.D., Consultant Physician and Professor of Endocrine Medicine
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PARC-Testosterone-D1/09/13
- 2013-001766-42 (EudraCT-nummer)
- IRAS project ID: 146877 (Annan identifierare: NHS London - West London & GTAC Research Ethics Committee)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .